Lawrence Berkeley National Laboratory
Recent Work

Title
The Fungal Cell Death Regulator czt-1 Is Allelic to acr-3.

Permalink
https://escholarship.org/uc/item/45f6c14q

Journal
Journal of fungi (Basel, Switzerland), 5(4)

ISSN
2309-608X

Authors
Gonçalves, A Pedro
McCluskey, Kevin
Glass, N Louise
et al.

Publication Date
2019-12-06

DOI
10.3390/jof5040114

Peer reviewed
Abstract: Fungal infections have far-reaching implications that range from severe human disease to a panoply of disruptive agricultural and ecological effects, making it imperative to identify and understand the molecular pathways governing the response to antifungal compounds. In this context, CZT-1 (cell death-activated zinc cluster transcription factor) functions as a master regulator of cell death and drug susceptibility in Neurospora crassa. Here we provide evidence indicating that czt-1 is allelic to acr-3, a previously described locus that we now found to harbor a point mutation in its coding sequence. This nonsynonymous amino acid substitution in a low complexity region of CZT-1/ACR-3 caused a robust gain-of-function that led to reduced sensitivity to acriflavine and staurosporine, and increased expression of the drug efflux pump abc-3. Thus, accumulating evidence shows that CZT-1 is an important broad regulator of the cellular response to various antifungal compounds that appear to share common molecular targets.

Keywords: antimicrobial drug resistance; cell death; CZT-1; ABC-3; acriflavine; staurosporine

1. Introduction

Human fungal infections have been, until recently, a largely underestimated public health problem with dramatic worldwide ramifications. Superficial skin infections occur in approximately a quarter of the world’s population, and invasive fungal infections, while less incident, are associated with high mortality rates—about 1.5 million people every year [1]. Fungal disease of plant and livestock has been leading to major social and economic costs in food systems and driving several animal species to extinction [2,3]. In addition, fungal infections are on the rise due to climate change-associated global warming [2,3].

Theoretically, most human fungal infections are relatively easy to treat provided that access to antifungal drugs is assured. However, a restricted number of drug options against fungal infections are available, including polyene (amphotericin B), echinocandin and azole drugs [4,5]. The success of available treatments is hampered by the development of antifungal drug resistance that can involve target modification, overexpression of efflux pump-encoding genes or hot spot amino acid
substitutions [4,5]. The induction of regulated forms of cell death is a common attribute of antifungal drugs and, therefore, understanding the molecular players and pathways regulating these cellular processes is of vital importance for the identification of suitable drug targets [6]. In order to achieve this goal, fungal models, such as the ascomycete *Neurospora crassa*, are of great importance due to the wide availability of genetic tools, such as targeted gene deletion strain collections and the accumulation of strains obtained over the years by classical forward genetics methodologies [7].

Staurosporine is a natural bacterial alkaloid, protein kinase inhibitor and prototypical anticancer drug that has been customarily used as a cell death inducer in various organisms, including fungi [6]. The *N. crassa* response to staurosporine involves well-defined alterations in the levels of cytosolic calcium, a process mediated by a putative transient receptor potential (TRP) channel at the plasma membrane and regulated by phospholipase C [8], as well as reactive oxygen species-dependent signaling [9]. At the transcriptional level, the *N. crassa* response to staurosporine is largely controlled by the Zn$_2$Cys$_6$ binuclear cluster transcription factor CZT-1 [10]. Here we report that czt-1 is allelic to *acr-3*, a locus that had been described in a mutant *N. crassa* strain obtained decades ago by random mutagenesis and that exhibits increased resistance to the fungal growth inhibitors acriflavine and malachite green [11]. We show that a single amino acid change in *czt-1* results in gain-of-function and is the likely cause for the enhanced tolerance to acriflavine of the *acr-3* strain. This report expands the importance of CZT-1 as an important regulator of susceptibility to antifungal compounds.

2. Materials and Methods

Routine cultivation of *N. crassa* was performed on Vogel’s minimal medium with 2% sucrose (plus 1.5% agar for solid medium). Asexual spores were obtained by growing strains in glass tubes with slanted medium for one week until full sporulation was evident. Mutant strains were obtained from the Fungal Genetics Stock Center [7]. The genomic sequence of NCU09974 in the *acr-3* mutant was obtained using a routine sequencing methodology [12]. Radial growth and spot assays were conducted as previously described [10]. Staurosporine was obtained from LC Laboratories and acriflavine and malachite green from Sigma-Aldrich. For quantitative real-time PCR experiments (qRT-PCR), asexual spores at a concentration of $10^6$ cells/mL were grown at 26 $^\circ$C in liquid VMM for 7 h; RNA was then isolated using the ZR Fungal/Bacterial RNA MicroPrep kit (Zymo Research), used for cDNA preparation using the SuperScript First-Strand Synthesis System kit (Life Technologies) and the relative expression of *abc-3* in different strains using *actin* (NCU04173) as the reference gene was obtained using the $2^{-\Delta\Delta C_t}$ calculation method from mixes containing previously described primers [13] and SYBR Green (Bio-Rad) that were analyzed in a Corbett Research Rotor-Gene 6000 thermocycler. Statistical analysis of qRT-PCR results was conducted on Prism 6 software (Graphpad).

3. Results and Discussion

The application of classical forward genetics methodologies in *N. crassa* has resulted in a collection of strains displaying morphological and developmental phenotypes that has been complemented with a genetic map of more than 1000 phenotypic markers and hundreds of other features like telomeres, centromeres, nucleolus organizer region, translocations, inversions and duplications [14]. More recently, whole genome resequencing has been used to identify the genome modifications underlying some of those phenotypes [15]. The *N. crassa* mutant FGSC1215 (*acr-3 mat-a*) was generated by UV light-based random mutagenesis and exhibits increased resistance to acriflavine [11]; *acr-3* (*acriflavine resistant-3*) is one of seven loci in *N. crassa* associated with altered tolerance to this drug [14,16]. Acriflavine (a mixture of 3,6-diamino-10-methylacridinium chloride (tryptaflavine) and 3,6-diaminoacridine) is a heteroaromatic dye with antibacterial, antiviral, anti-inflammatory and anticancer effects [17].

The *acr-3* locus has been mapped to linkage group I of *N. crassa*, between *un-16* and *suc* [14,16]. We have previously evaluated the presence of SNPs in NCU09975, a gene located in this region that encodes ABC-3, a drug efflux pump and member of the ATP-binding cassette (ABC) transporter family [13]. However, no SNPs in *abc-3* were found in strains FGSC1215 (*acr-3 mat-a*), FGSC1209
(acr-3 mat-A) or FGSC875 (acr-1 mat-a) [18]. Thus, we hypothesized that another candidate gene that could play a role in resistance to acriflavine in the acr-3 mutant was czt-1; czt-1 is also located in the genomic region previously identified to contain the acr-3 locus. In fact, czt-1 and abc-3 are adjacent to each other and CZT-1 is a transcriptional regulator of abc-3 [10,13]. Targeted sequencing of czt-1 (NCU09974) in FGSC1215 (acr-3) revealed a C>T non-synonymous mutation in its coding sequence (Figure 1A). Two transcripts or variants of czt-1, encoding proteins 780 and 685 amino acids long, respectively, have been annotated. The candidate mutation in czt-1 corresponded to a leucine to phenylalanine change in position 680 in the larger CZT-1 variant or position 585 in the shorter protein variant. CZT-1 is a Zn$_2$Cys$_6$ binuclear cluster transcription factor and the candidate mutation was located in a low complexity region with polar amino acid compositional bias but not in any of the conserved and previously described “DNA-binding domain”, “fungal-specific transcription factor domain” or “uncharacterized transcriptional regulatory protein domain” [10]. It will be interesting to biochemically characterize the different regions of the CZT-1 protein in future studies.

![Figure 1](image-url)

**Figure 1.** A point mutation in czt-1 explains the increased tolerance of the acr-3 mutant strain to acriflavine, malachite green and staurosporine. (A) DNA (top) and amino acid (bottom) sequence of a segment of czt-1 in wild type and acr-3 strains. A C>T (L>F) substitution was found in the acr-3 strain (underlined). Numbering corresponds to the larger transcript of czt-1. (B) Growth on solid Vogel’s minimal medium of wild type and acr-3 strains was followed across time. Images on the left were obtained 48 h after inoculation; on the right, colony diameter measurements. No statistically significant differences between the two strains were found. (C) Spot assays were performed to analyze the tolerance of strains labeled on the left to the indicated drugs. ACR, acriflavine; MG, malachite green; STS, staurosporine. (D) Relative expression of the abc-3 gene as measured by qPCR using actin as the reference gene. ANOVA followed by a Tukey post-hoc test showed that the expression of abc-3 in the acr-3 strain (“b”) was significantly higher than in wild type or Δczt-1 (“a”); p-value < 0.008. Three independent experiments were performed.

The acr-3 mutant grew slightly slower than the wild type (Figure 1B). We confirmed that the acr-3 mutant displays resistance to acriflavine using a spot assay; acriflavine at a concentration of 1 µg/mL almost completely inhibited the growth of the wild type, while the acr-3 mutant remained unaffected (Figure 1C). Strains where czt-1 or abc-3 were deleted showed similar sensitivity to acriflavine as the
wild type parental cells (Figure 1C). The acr-3 mutant was also more resistant to the antimicrobial malachite green, as previously reported [19], whereas a ∆czt-1 mutant was slightly more sensitive than the wild type (Figure 1C). Our previous work showed that the deletion of czt-1 results in high susceptibility to staurosporine [10]. Interestingly, acr-3 mutants were more resistant to staurosporine than the wild type strain (Figure 1C). Thus, the previously reported genetic mapping of the acr-3 allele that positioned the causative locus in the czt-1-abc-3 region [14,16], together with the sequence analysis of the acr-3 mutant strain showing a point mutation in czt-1, the drug susceptibility profiles of the ∆czt-1 and acr-3 strains, and the known function of CZT-1 as a drug tolerance regulator [10], all indicate that acr-3 is allelic to czt-1.

Since the ∆czt-1 deletion is a loss-of-function mutation, our comparison between czt-1 and acr-3 alleles suggested that the leucine to phenylalanine substitution in acr-3 caused a gain-of-function phenotype. In line with this hypothesis, the expression of abc-3, a key target of CZT-1 [10], was upregulated in the acr-3 strain (Figure 1D). ABC-3 exports staurosporine from the cytosol to the extracellular space [13] and could hypothetically function in a similar way with acriflavine. In addition to abc-3, CZT-1 regulates the expression of multiple ABC transporters, including azole resistance-associated cdr-4 as well as atrf and atrf-2 and others that lack functional characterization but contain typical ABC transporter domain features [10]. Thus, it appears plausible to speculate that the leucine to phenylalanine mutation in CZT-1/ACR-3 could result in an increase in the activity of one or more drug efflux pumps and, consequently, in increased tolerance to the antifungals acriflavine, staurosporine and malachite green. Our targeted gene sequencing approach does not allow us to rule out the possibility that potential mutations in other genes included in the range between un-16 and suc could be relevant for the drug sensitivity profile of the acr-3 strain, but our results suggest that the mutation found in the coding region of czt-1 is likely causative of the drug tolerance profile of the acr-3 mutant. Moreover, high doses of acriflavine (50 μg/mL) were almost ineffective against both mating type strains of acr-3 (Figure 1C), indicating that the mutation not only leads to gain-of-function of the respective protein, but also that its effect is very robust. In line with our results, a number of previous studies have reported point mutations in genes encoding Zn²Cys₆-family transcription factors that result in gain-of-function phenotypes [20,21].

In summary, we report here that the acr-3 strain not only exhibits increased resistance to acriflavine and malachite green, but also to the archetypal ATP-competitive kinase inhibitor staurosporine. Our data suggests that the causative genetic modification is likely a point mutation in the transcription factor CZT-1 that contains a Zn²Cys₆ DNA-binding domain that binds to its target promoters, including genes involved in cell death and drug resistance. Noteworthy, the acr-2 strain, which also displays increased resistance to acriflavine, harbors a gain-of-function point mutation on another Zn²Cys₆ transcription factor (NCU05733) [19]. Zn²Cys₆ proteins are fungal specific, constitute the largest family of transcription factors in N. crassa [22] and have been associated with drug resistance in various animal and plant pathogens [20,21,23]. Altogether, our data expand the role of CZT-1 as an important regulator of the fungal response to various drugs. In addition, the results show that acriflavine and staurosporine have overlapping intracellular targets; noteworthy, staurosporine is a protein kinase inhibitor [24] and acriflavine has been shown to inhibit the DNA-dependent protein kinase (DNA-PK) [25] and protein kinase C (PKC) [26]. Further studies will be needed to link these signaling transducers to their downstream transcriptional regulators during fungal cell death.

Author Contributions: Conceptualization, A.P.G., K.M., N.L.G. and A.V.; methodology, A.P.G. and K.M.; formal analysis, A.P.G. and A.V.; data curation, A.P.G.; writing—original draft preparation, A.P.G.; writing—review and editing, A.P.G., N.L.G. and A.V.

Funding: A.P.G. was recipient of a fellowship from Fundaçao Calouste Gulbenkian (104210) and a short-term fellowship from EMBO (329-2012). This work was supported by FCT Portugal (Fst-C/SAU/LA0002/2013 and FCOMP-01-0124-FEDER-037277 to A.V.), the European POCI program of QCAIII co-participated by FEDER (NORTE-07-0124-FEDER-000005) and the National Science Foundation (DBI 0742713 to the Fungal Genetics Stock Center – K.M.).

Acknowledgments: We thank Aric E. Wiest for his assistance.
Conflicts of Interest: The authors declare no conflict of interest.

References

1. Vallabhaneni, S.; Mody, R.K.; Walker, T.; Chiller, T. The Global Burden of Fungal Diseases. *Infect. Dis. Clin. N. Am.* 2016, 30, 1–11. [CrossRef] [PubMed]

2. Avery, S.V.; Singleton, I.; Magan, N.; Goldman, G.H. The fungal threat to global food security. *Fungal Biol.* 2019, 123, 555–557. [CrossRef] [PubMed]

3. Kettles, G.J.; Luna, E. Food security in 2044: How do we control the fungal threat? *Fungal Biol.* 2019, 123, 558–564. [CrossRef] [PubMed]

4. Perlin, D.S.; Rautemaa-Richardson, R.; Alastruey-Izquierdo, A. The global problem of antifungal resistance: prevalence, mechanisms, and management. *Lancet Infect. Dis.* 2017, 17, e383–e392. [CrossRef]

5. Shor, E.; Perlin, D.S. Coping with stress and the emergence of multidrug resistance in fungi. *PLoS Pathog.* 2015, 11, e1004668. [CrossRef]

6. Goncalves, A.P.; Heller, J.; Daskalov, A.; Videira, A.; Glass, N.L. Regulated Forms of Cell Death in Fungi. *Front. Microbiol.* 2017, 8, 1837. [CrossRef]

7. McCluskey, K.; Wiest, A.; Plamann, M. The Fungal Genetics Stock Center: a repository for 50 years of fungal genetics research. *J. Biosci.* 2010, 35, 119–126. [CrossRef]

8. Goncalves, A.P.; Cordeiro, J.M.; Monteiro, J.; Munoz, A.; Correia-de-Sa, P.; Read, N.D.; Videira, A. Activation of a TRP-like channel and intracellular Ca\(^{2+}\) dynamics during phospholipase-C-mediated cell death. *J. Cell Sci.* 2014, 127, 3817–3829. [CrossRef]

9. Goncalves, A.P.; Cordeiro, J.M.; Monteiro, J.; Lucchi, C.; Correia-de-Sa, P.; Videira, A. Involvement of mitochondrial proteins in calcium signaling and cell death induced by staurosporine in *Neurospora crassa*. *Biochim. Biophys. Acta* 2015, 1847, 1064–1074. [CrossRef]

10. Goncalves, A.P.; Hall, C.; Kowbel, D.J.; Glass, N.L.; Videira, A. CZT-1 is a novel transcription factor controlling cell death and natural drug resistance in *Neurospora crassa*. *G3 (Bethesda)* 2014, 4, 1091–1102. [CrossRef]

11. Hsu, K.S. Acriflavin resistance controlled by chromosomal genes in *Neurospora*. *Neurospora Newsl.* 1965, 8, 4–6. [CrossRef]

12. Sanger, F.; Nicklen, S.; Coulson, A.R. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* 1977, 74, 5463–5467. [CrossRef] [PubMed]

13. Fernandes, A.S.; Goncalves, A.P.; Castro, A.; Lopes, T.A.; Gardner, R.; Glass, N.L.; Videira, A. Modulation of fungal sensitivity to staurosporine by targeting proteins identified by transcriptional profiling. *Fungal Genet. Biol.* 2011, 48, 1130–1138. [CrossRef] [PubMed]

14. Perkins, D.D.; Radford, A.; Sachs, M.S. *The Neurospora Compendium: Chromosomal Loci*; Academic Press: San Diego, CA, USA, 2001.

15. McCluskey, K.; Wiest, A.E.; Grigoriev, I.V.; Lipzen, A.; Gardner, D.; Glass, N.L.; Videira, A. Analysis of the DNA sequence of the putative ABC transporter NCU09975 in *Neurospora crassa* strains carrying acriflavin resistance markers. *Fungal Genet. Rep.* 2012, 59, 26–29. [CrossRef] [PubMed]

16. Perkins, D.D.; Newmeyer, D.; Taylor, C.W.; Bennett, D.C. New markers and map sequences in *Neurospora crassa*, with a description of mapping by duplication coverage, and of multiple translocation stocks for testing linkage. *Genetica* 1969, 40, 247–278. [CrossRef]

17. Sabolova, D.; Kristian, P.; Kozurkova, M. Proflavine/acriflavine derivatives with versatile biological activities. *J. Appl. Toxicol.* 2019. [CrossRef]

18. Wiest, A.E.; Koch, S.; McCluskey, K. Analysis of the DNA sequence of the putative ABC transporter NCU09975 in *Neurospora crassa* strains carrying acriflavin resistance markers. *Fungal Genet. Rep.* 2012, 59, 26–29. [CrossRef]

19. Akiyama, M.; Nakashima, H. Molecular cloning of the acr-2 gene which controls acriflavine sensitivity in *Neurospora crassa*. *Biochim. Biophys. Acta* 1996, 1307, 187–192. [CrossRef]

20. Carvajal, E.; Van den Hazel, H.B.; Cybularz-Kolaczkowska, A.; Balzi, E.; Goffeau, A. Molecular and phenotypic characterization of yeast PDR1 mutants that show hyperactive transcription of various ABC multidrug transporter genes. *Mol. Gen. Genet.* 1997, 256, 406–415. [CrossRef]
21. Ferrari, S.; Ischer, F.; Calabrese, D.; Posteraro, B.; Sanguinetti, M.; Fadda, G.; Rohde, B.; Bauser, C.; Bader, O.; Sanglard, D. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. *PLoS Pathog.* 2009, 5, e1000268. [CrossRef]

22. Carrillo, A.J.; Schacht, P.; Cabrera, I.E.; Blahut, J.; Prudhomme, L.; Dietrich, S.; Bekman, T.; Mei, J.; Carrera, C.; Chen, V.; et al. Functional Profiling of Transcription Factor Genes in *Neurospora crassa*. *G3 (Bethesda)* 2017, 7, 2945–2956. [CrossRef] [PubMed]

23. Wang, Z.Q.; Meng, F.Z.; Zhang, M.M.; Yin, L.F.; Yin, W.X.; Lin, Y.; Hsiang, T.; Peng, Y.L.; Wang, Z.H.; Luo, C.X. A Putative Zn2Cys6 Transcription Factor Is Associated With Isoprothiolane Resistance in *Magnaporthe oryzae*. *Front. Microbiol.* 2018, 9, 2608. [CrossRef] [PubMed]

24. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; et al. A quantitative analysis of kinase inhibitor selectivity. *Nat. Biotechnol.* 2008, 26, 127–132. [CrossRef] [PubMed]

25. Cao, J.; Lin, G.; Gong, Y.; Pan, P.; Ma, Y.; Huang, P.; Ying, M.; Hou, T.; He, Q.; Yang, B. DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan. *Cancer Lett.* 2016, 383, 115–124. [CrossRef]

26. Hannun, Y.A.; Bell, R.M. Aminoacridines, potent inhibitors of protein kinase C. *J. Biol. Chem.* 1988, 263, 5124–5131.

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).